<DOC>
	<DOCNO>NCT00080808</DOCNO>
	<brief_summary>RATIONALE : Nerve-sparing radical prostatectomy nerve graft follow standard therapy erectile dysfunction may effective help patient prostate cancer improve sexual satisfaction quality life . It yet know whether erectile dysfunction therapy nerve-sparing prostatectomy effective without nerve grafting . PURPOSE : This randomized phase II trial study nerve graft standard therapy see well work compare standard therapy alone treat erectile dysfunction patient undergo nerve-sparing radical prostatectomy localized prostate cancer .</brief_summary>
	<brief_title>Nerve-Sparing Radical Prostatectomy With Without Nerve Grafting Followed Standard Therapy Erectile Dysfunction Treating Patients With Localized Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy erectile dysfunction rehabilitation unilateral cavernous nerve-sparing radical prostatectomy versus without unilateral autologous interposition sural nerve graft patient clinically localized prostate cancer . - Compare potency rate patient treat regimen . - Compare erection quality patient treat regimen . - Compare time return spontaneous erectile activity patient treat regimen . - Compare feasibility regimens patient . - Compare quality life sexual satisfaction patient treat regimen . - Compare change penile erectile length circumference patient treat regimen . - Compare relative morbidity patient treat regimen . OUTLINE : This randomize , open-label study . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo unilateral cavernous nerve-sparing radical prostatectomy unilateral autologous interposition sural nerve grafting . Beginning 6 week surgery , patient undergo erectile dysfunction rehabilitation comprise follow : oral sildenafil ( occasion require ) , use vacuum erection device 10 minute daily , intracavernous Triplemix ( prostaglandin E1 , papaverine , phentolamine ) inject twice weekly , MUSE ( suppository urethra erection ) therapy . Erectile dysfunction rehabilitation may continue 2 year return adequate spontaneous erectile activity . - Arm II : Patients undergo unilateral cavernous nerve-sparing radical prostatectomy ( without sural nerve graft ) erectile dysfunction rehabilitation arm I . In arm , treatment continue absence unacceptable toxicity . Quality life sexual history assess baseline , 6 week postoperatively , 4 , 8 , 12 , 16 month , every 4 month 2 year return spontaneous erectile activity . Patients follow every 4 month 2 year . PROJECTED ACCRUAL : A total 200 patient ( 120 arm I 80 arm II ) accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Phentolamine</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Alprostadil</mesh_term>
	<mesh_term>Papaverine</mesh_term>
	<criteria>1 . Patient must candidate unilateral nerve spar radical retropubic prostatectomy . ) Gleason score 7 less core side spar 2 . Patient must discernable preoperative erectile dysfunction , define ability successful penetration least 75 % attempt . 3 . Patient must &lt; /= 65 year age time study enrollment . 4 . Patient must peripheral neuropathy preclude procurement sural nerve graft 5 . Patient must significant psychiatric illness demonstrable vasculogenic source impotence . 6 . No prior history pelvic irradiation androgen deprivation therapy ( LHRH agonists antiandrogens )</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>perioperative/postoperative complication</keyword>
	<keyword>sexual dysfunction infertility</keyword>
	<keyword>sexuality reproductive issue</keyword>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>prostaglandin E1</keyword>
	<keyword>papaverine</keyword>
	<keyword>phentolamine</keyword>
	<keyword>Nerve-sparing radical prostatectomy</keyword>
	<keyword>nerve graft</keyword>
</DOC>